# Integer Holdings Corp: overview

ITGR · NYSE · CIK 1114483 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/itgr.md) · [Financials](/companies/itgr/financials.md) · [Filings](/companies/itgr/filings.md) · [Insiders](/companies/itgr/insiders.md)

Latest reported revenue: [$464.1m](/filings/0001114483-26-000027.md) for Q2 FY2026, three months to 2026-07-03, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001114483-26-000027).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [431](/filings/0001114483-25-000134.md) | [449 d](/filings/0001114483-26-000003.md) | [437](/filings/0001114483-26-000015.md) | [476](/filings/0001114483-26-000027.md) | [468](/filings/0001114483-25-000134.md) | [472 d](/filings/0001114483-26-000003.md) | [440](/filings/0001114483-26-000015.md) | [464](/filings/0001114483-26-000027.md) |
| Gross margin | % | [27.0%](/filings/0001114483-25-000134.md) | [26.0% d](/filings/0001114483-26-000003.md) | [27.5%](/filings/0001114483-26-000015.md) | [27.1%](/filings/0001114483-26-000027.md) | [27.0%](/filings/0001114483-25-000134.md) | [26.4% d](/filings/0001114483-26-000003.md) | [24.9%](/filings/0001114483-26-000015.md) | [24.3%](/filings/0001114483-26-000027.md) |
| Operating margin | % | [13.4%](/filings/0001114483-25-000134.md) | [12.7% d](/filings/0001114483-26-000003.md) | [11.3%](/filings/0001114483-26-000015.md) | [12.5%](/filings/0001114483-26-000027.md) | [12.1%](/filings/0001114483-25-000134.md) | [11.8% d](/filings/0001114483-26-000003.md) | [7.2%](/filings/0001114483-26-000015.md) | [7.4%](/filings/0001114483-26-000027.md) |
| Net margin | % | [8.2%](/filings/0001114483-25-000134.md) | [7.3% d](/filings/0001114483-26-000003.md) | [(5.1%)](/filings/0001114483-26-000015.md) | [7.8%](/filings/0001114483-26-000027.md) | [8.5%](/filings/0001114483-25-000134.md) | [10.3% d](/filings/0001114483-26-000003.md) | [3.8%](/filings/0001114483-26-000015.md) | [5.1%](/filings/0001114483-26-000027.md) |
| Diluted EPS | $ per share | [0.99](/filings/0001114483-25-000134.md) | not reported | [(0.66)](/filings/0001114483-26-000015.md) | [1.04](/filings/0001114483-26-000027.md) | [1.11](/filings/0001114483-25-000134.md) | not reported | [0.48](/filings/0001114483-26-000015.md) | [0.69](/filings/0001114483-26-000027.md) |
| Free cash flow | $m | [45.5 d](/filings/0001114483-25-000134.md) | [44.1 d](/filings/0001114483-26-000003.md) | [6.1](/filings/0001114483-26-000015.md) | [24.9 d](/filings/0001114483-26-000027.md) | [46.3 d](/filings/0001114483-25-000134.md) | [27.9 d](/filings/0001114483-26-000003.md) | [0.7](/filings/0001114483-26-000015.md) | [37.0 d](/filings/0001114483-26-000027.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,221](/filings/0001114483-24-000034.md) | [1,331](/filings/0001114483-25-000034.md) | [1,556](/filings/0001114483-26-000003.md) | [1,717](/filings/0001114483-26-000003.md) | [1,854](/filings/0001114483-26-000003.md) |
| Gross margin | % | [27.6%](/filings/0001114483-24-000034.md) | [26.0%](/filings/0001114483-25-000034.md) | [26.3%](/filings/0001114483-26-000003.md) | [26.7%](/filings/0001114483-26-000003.md) | [27.0%](/filings/0001114483-26-000003.md) |
| Operating margin | % | [11.1%](/filings/0001114483-24-000034.md) | [8.5%](/filings/0001114483-25-000034.md) | [10.5%](/filings/0001114483-26-000003.md) | [12.1%](/filings/0001114483-26-000003.md) | [11.9%](/filings/0001114483-26-000003.md) |
| Net margin | % | [7.9%](/filings/0001114483-24-000034.md) | [5.0%](/filings/0001114483-25-000034.md) | [5.8%](/filings/0001114483-26-000003.md) | [7.0%](/filings/0001114483-26-000003.md) | [5.5%](/filings/0001114483-26-000003.md) |
| Diluted EPS | $ per share | [2.91](/filings/0001114483-24-000034.md) | [1.99](/filings/0001114483-25-000034.md) | [2.69](/filings/0001114483-26-000003.md) | [3.36](/filings/0001114483-26-000003.md) | [2.89](/filings/0001114483-26-000003.md) |
| Free cash flow | $m | [103](/filings/0001114483-24-000034.md) | [41.7](/filings/0001114483-25-000034.md) | [60.3](/filings/0001114483-26-000003.md) | [99.8](/filings/0001114483-26-000003.md) | [105](/filings/0001114483-26-000003.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/itgr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $500.3m | 5,353,741 |  | Added +47,900 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $210.0m | 2,247,031 |  | Added +277,898 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $190.7m | 2,040,469 |  | Reduced −6,497 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $152.1m | 1,627,784 |  | Added +143,388 |
| [NOMURA HOLDINGS INC](/funds/1163653.md) | 2026-06-30 | $145.3m | 1,554,450 |  | Added +1,106,089 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $143.2m | 1,531,843 |  | Reduced −5,444 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $132.0m | 1,413,174 |  | Added +14,888 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $125.8m | 1,345,748 |  | Reduced −193,535 |
| [Irenic Capital Management LP](/funds/1929389.md) | 2026-06-30 | $118.1m | 1,264,259 |  | Added +596 |
| [EARNEST PARTNERS LLC](/funds/1102578.md) | 2026-06-30 | $94.2m | 1,008,519 |  | Reduced −32,629 |

## Recent filings

[All 1,309 filings](/companies/itgr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 08:00 ET | [8-K](/filings/0001171843-26-006960.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-006960 |
| 2026-10-21 | 17:10 ET | [8-K](/filings/0000950103-26-015975.md) | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950103-26-015975 |
| 2026-10-14 | 08:47 ET | [8-K](/filings/0000950103-26-015548.md) | 8.01 Other events | 0000950103-26-015548 |
| 2026-10-13 | 20:22 ET | [SCHEDULE 13D](/filings/0001140361-26-039472.md) | Ownership report, active investor | 0001140361-26-039472 |
| 2026-10-02 | 16:05 ET | [8-K](/filings/0001171843-26-006370.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-006370 |
| 2026-09-30 | 08:21 ET | [8-K](/filings/0000950103-26-014831.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950103-26-014831 |
| 2026-08-04 | 17:26 ET | [10-Q](/filings/0001114483-26-000027.md) | Quarterly report, period 2026-07-03 | 0001114483-26-000027 |
| 2026-08-04 | 16:32 ET | [8-K](/filings/0000950103-26-011881.md) | 1.01 Entry into a material agreement; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950103-26-011881 |
| 2026-08-03 | 16:44 ET | [8-K](/filings/0000950103-26-011683.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950103-26-011683 |
| 2026-08-03 | 06:32 ET | [8-K](/filings/0001171843-26-005137.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005137 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001114483-26-000003.md), filed Feb 23, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1114483
- Tickers: ITGR
- Exchange: NYSE
- SIC code: 3845 Electromedical & Electrotherapeutic Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 08:06 ET. No prices; not investment advice.